|
|
Previous Article | Table of Contents | Next Article 
BCL-2 but not its Epstein-Barr virus-encoded homologue, BHRF1, is commonly
expressed in posttransplantation lymphoproliferative disorders [see
comments]
PG Murray, LJ Swinnen, CM Constandinou, JM Pyle, TJ Carr, JM Hardwick and RF Ambinder
Johns Hopkins Oncology Center, Baltimore, MD 21231, USA.
Posttransplantation lymphoproliferative disease (PTLD) is virtually always
associated with Epstein-Barr virus (EBV) infection. BCL-2 and other
proteins that confer resistance to apoptosis have been implicated in the
pathogenesis of a variety of malignancies including lymphomas. One EBV
protein, BHRF1, is a homologue of BCL-2, whereas another, the latency
membrane protein 1 (LMP-1), upregulates BCL-2 expression in vitro. In the
present study, we used immunohistochemistry to study the expression of
these viral and cellular proteins as well as a variety of other EBV-encoded
proteins in PTLD. BHRF1 was not detected in any PTLD specimen, whereas
BCL-2 was shown in 12 of 17 lesions examined. With one exception, all
LMP1-positive cases also expressed BCL-2 and the absence of LMP1 was always
associated with a lack of BCL-2 expression. The results do not support a
role for the EBV homologue of BCL-2 in PTLD, but they do support a role for
viral induction of BCL-2 expression.
Volume 87,
Issue 2,
pp. 706-711,
01/15/1996
Copyright © 1996 by The American Society of Hematology

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
D. M. Walling, A. J. Ray, J. E. Nichols, C. M. Flaitz, and C. M. Nichols
Epstein-Barr Virus Infection of Langerhans Cell Precursors as a Mechanism of Oral Epithelial Entry, Persistence, and Reactivation
J. Virol.,
July 1, 2007;
81(13):
7249 - 7268.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Dutton, C. B. Woodman, M. B. Chukwuma, J. I. K. Last, W. Wei, M. Vockerodt, K. R. N. Baumforth, J. R. Flavell, M. Rowe, A. M. R. Taylor, et al.
Bmi-1 is induced by the Epstein-Barr virus oncogene LMP1 and regulates the expression of viral target genes in Hodgkin lymphoma cells
Blood,
March 15, 2007;
109(6):
2597 - 2603.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Landais, X. Saulquin, M. Bonneville, and E. Houssaint
Long-Term MHC Class II Presentation of the EBV Lytic Protein BHRF1 by EBV Latently Infected B Cells following Capture of BHRF1 Antigen
J. Immunol.,
December 15, 2005;
175(12):
7939 - 7946.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. M. Ghobrial, T. M. Habermann, M. J. Maurer, S. M. Geyer, K. M. Ristow, T. S. Larson, R. C. Walker, S. M. Ansell, W. R. Macon, G. G. Gores, et al.
Prognostic Analysis for Survival in Adult Solid Organ Transplant Recipients With Post-Transplantation Lymphoproliferative Disorders
J. Clin. Oncol.,
October 20, 2005;
23(30):
7574 - 7582.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Pfeffer, M. Zavolan, F. A. Grasser, M. Chien, J. J. Russo, J. Ju, B. John, A. J. Enright, D. Marks, C. Sander, et al.
Identification of Virus-Encoded MicroRNAs
Science,
April 30, 2004;
304(5671):
734 - 736.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Dutton, J. D. O'Neil, A. E. Milner, G. M. Reynolds, J. Starczynski, J. Crocker, L. S. Young, and P. G. Murray
Expression of the cellular FLICE-inhibitory protein (c-FLIP) protects Hodgkin's lymphoma cells from autonomous Fas-mediated death
PNAS,
April 27, 2004;
101(17):
6611 - 6616.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Loomis, R. Carbone, M. Reiss, and J. Lacy
Bcl-2 Antisense (G3139, Genasense) Enhances the in Vitro and in Vivo Response of Epstein-Barr Virus-associated Lymphoproliferative Disease to Rituximab
Clin. Cancer Res.,
May 1, 2003;
9(5):
1931 - 1939.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Q. Tao, J. Yang, H. Huang, L. J. Swinnen, and R. F. Ambinder
Conservation of Epstein-Barr Virus Cytotoxic T-Cell Epitopes in Posttransplant Lymphomas : Implications for Immune Therapy
Am. J. Pathol.,
May 1, 2002;
160(5):
1839 - 1845.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. M. Moore, J. S. Cannon, Y. C. Tanhehco, F. M. Hamzeh, and R. F. Ambinder
Induction of Epstein-Barr Virus Kinases To Sensitize Tumor Cells to Nucleoside Analogues
Antimicrob. Agents Chemother.,
July 1, 2001;
45(7):
2082 - 2091.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Haddad, S. Paczesny, V. Leblond, J.-M. Seigneurin, M. Stern, A. Achkar, M. Bauwens, V. Delwail, D. Debray, C. Duvoux, et al.
Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial
Blood,
March 15, 2001;
97(6):
1590 - 1597.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Leblond, N. Dhedin, M.-F. M. Bruneel, S. Choquet, O. Hermine, R. Porcher, S. N. Quoc, F. Davi, F. Charlotte, R. Dorent, et al.
Identification of Prognostic Factors in 61 Patients With Posttransplantation Lymphoproliferative Disorders
J. Clin. Oncol.,
February 1, 2001;
19(3):
772 - 778.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. J. Swinnen
Post-transplant Lymphoproliferative Disorders: Implications for Acquired Immunodeficiency Syndrome-Associated Malignancies
J Natl Cancer Inst Monographs,
December 1, 2000;
2000(28):
38 - 43.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K J Flavell and P G Murray
Hodgkin's disease and the Epstein-Barr virus
Mol. Pathol.,
October 1, 2000;
53(5):
262 - 269.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
M. E. Guinness, J. L. Kenney, M. Reiss, and J. Lacy
Bcl-2 Antisense Oligodeoxynucleotide Therapy of Epstein-Barr Virus-associated Lymphoproliferative Disease in Severe Combined Immunodeficient Mice
Cancer Res.,
October 1, 2000;
60(19):
5354 - 5358.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
B. Damania, J.-K. Choi, and J. U. Jung
Signaling Activities of Gammaherpesvirus Membrane Proteins
J. Virol.,
February 15, 2000;
74(4):
1593 - 1601.
[Full Text]
|
 |
|

|
 |

|
 |
 
J. Yang, V. M. Lemas, I. W. Flinn, C. Krone, and R. F. Ambinder
Application of the ELISPOT assay to the characterization of CD8+ responses to Epstein-Barr virus antigens
Blood,
January 1, 2000;
95(1):
241 - 248.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Q. Tao, L. J. Swinnen, J. Yang, G. Srivastava, K. D. Robertson, and R. F. Ambinder
Methylation Status of the Epstein-Barr Virus Major Latent Promoter C in Iatrogenic B Cell Lymphoproliferative Disease : Application of PCR-Based Analysis
Am. J. Pathol.,
August 1, 1999;
155(2):
619 - 625.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. G. Murray, L. J. Billingham, H. T. Hassan, J. R. Flavell, P. N. Nelson, K. Scott, G. Reynolds, C. M. Constandinou, D. J. Kerr, E. C. Devey, et al.
Effect of Epstein-Barr Virus Infection on Response to Chemotherapy and Survival in Hodgkin's Disease
Blood,
July 15, 1999;
94(2):
442 - 447.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. L. Marshall, C. Yim, E. Gustafson, T. Graf, D. R. Sage, K. Hanify, L. Williams, J. Fingeroth, and R. W. Finberg
Epstein-Barr Virus Encodes a Novel Homolog of the bcl-2 Oncogene That Inhibits Apoptosis and Associates with Bax and Bak
J. Virol.,
June 1, 1999;
73(6):
5181 - 5185.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
S. Julien, M. Radosavljevic, N. Labouret, S. Camilleri-Broet, F. Davi, M. Raphael, T. Martin, and J.-L. Pasquali
AIDS Primary Central Nervous System Lymphoma: Molecular Analysis of the Expressed VH Genes and Possible Implications for Lymphomagenesis
J. Immunol.,
February 1, 1999;
162(3):
1551 - 1558.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Benkerrou, J.-P. Jais, V. Leblond, A. Durandy, L. Sutton, P. Bordigoni, J. L. Garnier, J. Le Bidois, F. Le Deist, S. Blanche, et al.
Anti-B-Cell Monoclonal Antibody Treatment of Severe Posttransplant B-Lymphoproliferative Disorder: Prognostic Factors and Long-Term Outcome
Blood,
November 1, 1998;
92(9):
3137 - 3147.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. L. Kenney, M. E. Guinness, T. Curiel, and J. Lacy
Antisense to the Epstein-Barr Virus (EBV)-Encoded Latent Membrane Protein 1 (LMP-1) Suppresses LMP-1 and Bcl-2 Expression and Promotes Apoptosis in EBV-Immortalized B Cells
Blood,
September 1, 1998;
92(5):
1721 - 1727.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Derfuss, H. Fickenscher, M. S. Kraft, G. Henning, D. Lengenfelder, B. Fleckenstein, and E. Meinl
Antiapoptotic Activity of the Herpesvirus Saimiri-Encoded Bcl-2 Homolog: Stabilization of Mitochondria and Inhibition of Caspase-3-Like Activity
J. Virol.,
July 1, 1998;
72(7):
5897 - 5904.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. G. Horenstein, R. G. Nador, A. Chadburn, E. M. Hyjek, G. Inghirami, D. M. Knowles, and E. Cesarman
Epstein-Barr Virus Latent Gene Expression in Primary Effusion Lymphomas Containing Kaposi's Sarcoma-Associated Herpesvirus/Human Herpesvirus-8
Blood,
August 1, 1997;
90(3):
1186 - 1191.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|